We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by University of Vermont.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01341171
First Posted: April 25, 2011
Last Update Posted: April 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
American Cancer Society, Inc.
Information provided by:
University of Vermont
July 7, 2010
April 25, 2011
April 25, 2011
August 2009
October 2010   (Final data collection date for primary outcome measure)
Angiogenic Protein levels [ Time Frame: following 6 months of therapy ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins
Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
Not Provided
Observational
Not Provided
Not Provided
Retention:   Samples Without DNA
Description:
serum, plasma, platelet activated samples
Non-Probability Sample
Women using tamoxifen or aromatase inhibitor therapy for greater than 6 months
Breast Cancer
Not Provided
tamoxifen or aromatase inhibitors
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
September 2012
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist

Exclusion Criteria:

  • Use of heparin, warfarin
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01341171
V0805
No
Not Provided
Not Provided
Chris E. Holmes, MD, PhD, University of Vermont
University of Vermont
American Cancer Society, Inc.
Principal Investigator: Chris E Holmes, MD, PhD University of Vermont
University of Vermont
April 2011